IRIS - Res&Arch Institutional Research Information System - Research & Archive

SALVADORI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.805
AS - Asia 1.320
EU - Europa 1.241
SA - Sud America 241
Continente sconosciuto - Info sul continente non disponibili 131
AF - Africa 48
OC - Oceania 8
Totale 4.794
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.746
SG - Singapore 560
IT - Italia 505
BR - Brasile 195
CN - Cina 170
HK - Hong Kong 161
IE - Irlanda 151
RU - Federazione Russa 105
KR - Corea 94
DE - Germania 84
VN - Vietnam 76
FR - Francia 69
NL - Olanda 52
GB - Regno Unito 47
BD - Bangladesh 46
IN - India 44
SE - Svezia 39
FI - Finlandia 37
AT - Austria 30
CA - Canada 29
TR - Turchia 29
RO - Romania 24
JP - Giappone 21
IQ - Iraq 20
PH - Filippine 19
PL - Polonia 17
CO - Colombia 16
ES - Italia 16
ZA - Sudafrica 16
BE - Belgio 13
UA - Ucraina 13
AR - Argentina 10
CH - Svizzera 10
MX - Messico 10
PK - Pakistan 10
SA - Arabia Saudita 8
AU - Australia 7
EC - Ecuador 7
IR - Iran 7
EG - Egitto 6
ID - Indonesia 6
MA - Marocco 6
TN - Tunisia 6
UZ - Uzbekistan 6
MD - Moldavia 5
MY - Malesia 5
TW - Taiwan 5
CL - Cile 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
IL - Israele 4
JM - Giamaica 4
JO - Giordania 4
KH - Cambogia 4
LB - Libano 4
AL - Albania 3
BA - Bosnia-Erzegovina 3
HU - Ungheria 3
KE - Kenya 3
KG - Kirghizistan 3
LT - Lituania 3
OM - Oman 3
PA - Panama 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
KZ - Kazakistan 2
NI - Nicaragua 2
NP - Nepal 2
PE - Perù 2
PY - Paraguay 2
UY - Uruguay 2
AM - Armenia 1
CV - Capo Verde 1
EE - Estonia 1
EU - Europa 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
IS - Islanda 1
ML - Mali 1
MQ - Martinica 1
MR - Mauritania 1
MW - Malawi 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
TZ - Tanzania 1
VC - Saint Vincent e Grenadine 1
Totale 4.664
Salva come PNG Salva come JPEG
Città #
Singapore 449
Chandler 191
San Jose 187
Hong Kong 149
Dublin 147
Perugia 136
Ashburn 129
Santa Clara 71
Boardman 58
San Mateo 56
Los Angeles 47
The Dalles 47
Beijing 44
Moscow 42
Lauterbourg 38
New York 37
Altamura 34
Ann Arbor 32
Redmond 31
Turin 29
Dearborn 28
Medford 28
Munich 28
Princeton 27
Seoul 27
Vienna 26
Ho Chi Minh City 23
São Paulo 22
Wilmington 22
Andover 20
Bucharest 20
Bologna 19
Lawrence 18
Seongnam-si 18
Piscataway 16
Milan 15
Orem 14
Tokyo 14
Brussels 13
Dallas 13
Denver 12
Falkenstein 12
Hanoi 12
Montreal 12
Rome 12
Warsaw 12
Amsterdam 11
Falls Church 11
Boston 10
Johannesburg 10
London 10
Nuremberg 10
Turku 10
Atlanta 9
Brooklyn 9
Cebu City 9
Istanbul 9
Parma 9
Phoenix 9
Baghdad 8
Council Bluffs 8
Frankfurt am Main 8
Groningen 8
Helsinki 8
Toronto 8
Chennai 7
Da Nang 7
Houston 7
Mumbai 7
Redwood City 7
San Francisco 7
Seodaemun-gu 7
Brasília 6
Collazzone 6
Des Moines 6
Dhaka 6
Florence 6
Glasgow 6
Incheon 6
Norwalk 6
Saint Petersburg 6
Buffalo 5
Cairo 5
Columbus 5
Dong Ket 5
Hefei 5
New Delhi 5
Stockholm 5
Ankara 4
City of London 4
Jakarta 4
Jinju 4
Karaj 4
Konya 4
Lahore 4
Mainz 4
Naples 4
Olomouc 4
Paris 4
Pavia 4
Totale 2.797
Salva come PNG Salva come JPEG
Nome #
Beneficial effects of horsetail (Equisetum arvense) in experimental models of sarcopenia and osteoporosis 287
Pharmacological targeting of the receptor for advanced glycation end-products (RAGE) to counteract cancer cachexia 200
Histological muscle characterization in hypertrophied Marchigiana cattle breed 179
Intraperitoneal injection of microencapsulated Sertoli cells restores muscle morphology and performance in dystrophic mice 178
Targeting RAGE prevents muscle wasting and prolongs survival in cancer cachexia 156
Identification of natural products able to counteract the formation of advanced glycation end-products (AGEs) sustaining muscle atrophy 152
RAGE in the pathophysiology of skeletal muscle. 150
Equisetum arvense standardized extract hinders age-related sarcopenia 144
Generation of an mdx/Ager–/– double mutant mouse. Preliminary data on skeletal muscle architecture. 142
Absence of RAGE in an animal experimental model of Duchenne muscular dystrophy results in reduced muscle necrosis and inflammation 142
Sertoli cells protect C2C12 myotubes against atrophy and induce utrophin expression in canine and human dystrophic myotubes. 138
Toward the identification of receptor for advanced glycation end-products (RAGE) as a muscle biomarker of cancer cachexia. 138
Natural products to counteract muscle atrophy 136
Sertoli cell-secreted factors have promyogenic and antifibrotic properties on human DMD myoblasts with different mutations. 134
Ablation of RAGE (receptor for advanced glycation end-products) translates into reduced tumorigenic and cachectic potential in LLC-tumor bearing mice 133
Effects of intraperitoneal injection of microencapsulated Sertoli cells on chronic and presymptomatic dystrophic mice 131
RAGE and its ligands, S100B and HMGB1, are molecular determinants of cancer-induced muscle wasting. 130
Screening of 100 plant extracts for the development of a herbal product effective against muscle atrophy 130
Targeting RAGE as a potential therapeutic approach to Duchenne muscular dystrophy 125
Involvement of a RAGE/p38MAPK/myogenin axis in cancer cachexia. 116
Beneficial effects of horsetail (Equisetum arvense) in in vitro models of sarcopenia and osteoporosis 110
Mdx/Ager–/– mice show reduced muscle necrosis and inflammation compared with mdx mice 110
Receptor for advanced glycation end-products (RAGE) as a biomarker of muscle wasting in cancer conditions 110
KYMASIN UP Natural Product Inhibits Osteoclastogenesis and Improves Osteoblast Activity by Modulating Src and p38 MAPK 109
Identification of Withania somnifera-Silybum marianum-Trigonella foenum-graecum Formulation as a Nutritional Supplement to Contrast Muscle Atrophy and Sarcopenia 108
Microencapsulated Sertoli cells sustain myoblast proliferation without affecting the myogenic potential. In vitro data 108
Employment of Microencapsulated Sertoli Cells as a New Tool to Treat Duchenne Muscular Dystrophy 107
Hyperactivated rage in comorbidities as a risk factor for severe covid-19—the role of rage-ras crosstalk 106
Equisetum arvense standardized dried extract hinders age-related osteosarcopenia. 104
Do porcine Sertoli cells represent an opportunity for Duchenne muscular dystrophy? 102
Use of Sertoli cells to treat DMD patients is supported by their immunomodulatory rather than immunosuppressive effect 100
Novel data support the use of microencapsulated Sertoli cells as a potential treatment of DMD patients. 97
The receptor RAGE: a potential molecular target in cancer cachexia 94
Sertoli cells induce utrophin expression in human DMD myotubes with different mutations and exert promyogenic and antifibrotic effects 91
The novel DMD experimental model, mdx/Ager–/– mouse reveals a role of RAGE in inflammatory processes in dystrophic muscles. 78
Grafted Sertoli Cells Exert Immunomodulatory Non-Immunosuppressive Effects in Preclinical Models of Infection and Cancer 75
Sertoli cells improve myogenic differentiation, reduce fibrogenic markers, and induce utrophin expression in human dmd myoblasts 72
Sertoli cells have promyogenic and antifibrotic effects, and induce utrophin expression in human DMD myotubes with different mutations in a heregulin β1/ErbB2/ERK1/2-dependent manner 54
Diet-Derived Advanced Glycation End-Products (AGEs) Induce Muscle Wasting In Vitro, and a Standardized Vaccinium macrocarpon Extract Restrains AGE Formation and AGE-Dependent C2C12 Myotube Atrophy 18
Totale 4.794
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.595
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.595
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022247 0 0 9 17 6 8 8 75 10 32 43 39
2022/2023548 30 104 3 49 44 61 1 25 198 2 22 9
2023/2024286 15 23 5 23 8 21 80 4 4 14 22 67
2024/20251.143 43 83 134 70 112 55 113 118 146 68 143 58
2025/20261.847 102 88 73 216 229 158 309 115 175 151 175 56
2026/2027251 158 58 35 0 0 0 0 0 0 0 0 0
Totale 4.794